Capricor completes patient enrollment in initial phase of DYNAMIC trial of heart failure drug candidate
CAP-1002 is being developed to treat advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below. A total
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.